Thermo Fisher Scientific (TMO) Cash & Current Investments (2009 - 2026)

Thermo Fisher Scientific has disclosed Cash & Current Investments across 18 years of filings, most recently posting $3.3 billion for Q1 2026.

• Quarterly Cash & Current Investments fell 45.25% year-over-year to $3.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 billion (down 45.25% YoY) and the FY2025 annual result came in at $10.1 billion, up 81.42% from the prior year.
• Cash & Current Investments retreated to $3.3 billion in Q1 2026, from $10.1 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $10.1 billion in Q4 2025 and troughed at $1.9 billion in Q3 2022.
• A 5-year average of $5.6 billion and a median of $5.9 billion in 2025 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 75.73% — and 2024, when it soared 181.62%.
• Tracing TMO's Cash & Current Investments over 5 years: stood at $8.5 billion in 2022, then retreated by 5.21% to $8.1 billion in 2023, then plunged by 31.06% to $5.6 billion in 2024, then jumped by 81.42% to $10.1 billion in 2025, then plunged by 67.78% to $3.3 billion in 2026.
• Business Quant data shows TMO's Cash & Current Investments at $3.3 billion in Q1 2026, $10.1 billion in Q4 2025, and $3.5 billion in Q3 2025.